Abstract
Objective To investigate the changes levels of serum interleukin 6(IL-6), tumor necrosis factor α(TNF-α) and procalcitonin(PCT) and prognosis of patients with septic shock with the treatmentof ulinastatin and Atomolan. Methods Sixty cases patients with septic shock in Fifth Hospital Affiliated to Guangzhou Medical University from May 2015 to April 2016 were selected, and divided into ulinastatin group, Atomolan group and combined group according to the table of random numbers, each group with 20 cases.Hospital stay in ICU, mechanical ventilation time, APACHEⅡ score after treatment, the level of IL-6, TNF-α, PCT, malondialdehyde(MDA), superoxide dismutase(SOD) before and after treatment, and prognosis of patients of three groups were compared. Results Hospital stay in ICU, mechanical ventilation time, APACHEⅡ score after treatment of combined group were significantly lower than ulinastatin group and Atomolan group, the differences were statistically significant(P 0.05). After treatment, the level of IL-6, TNF-α, PCT and MDA of the combined group were significantly lower than that of ulinastatin group and Atomolan group, while SOD was significantly higher than the other two groups, the differences were statistically significant(P<0.05). The MODS incidence, mortality rates of ulinastatin group were 30.00%(6/20), 20.00%(4/20), of Atomolan group were 35.00%(7/20), 15.00%(3/20), of combined group were 5.00%(1/20), 5.00%(1/20). The MODS incidence, mortality rates of combined group were lower than the other two groups(P<0.05). Conclusion Ulinastatin combined with Atomolan in treatment of septic shock with remarkable results, can significantly improve the serum IL-6, TNF-α, PCT and other important factors, optimize the prognosis, it is worthy of promotion. Key words: Ulinastatin; Atomolan; Septic shock; Interleukin -6; Tumor necrosis factor α; Procalcitonin; Prognosis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
